Action CTX CRESCITA THERAPEUTICS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Crescita Therapeutics Inc.

Actions

CTX

CA2258471028

Marché Fermé - Toronto S.E.
Autres places de cotation
 18:59:15 09/05/2024 		Varia. 5j. Varia. 1 janv.
0,435 CAD 0,00% Graphique intraday de Crescita Therapeutics Inc. +1,16% -11,22%
08/05 La perte de Crescita Therapeutics au premier trimestre s'aggrave, les revenus augmentent MT
08/05 Crescita Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Crescita Therapeutics Q1 Loss Widens, Revenue Rises
Crescita Therapeutics Brief: Q1 Revenue was $4.996 Million
Crescita Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Crescita Reports First Quarter 2024 Results
Crescita Therapeutics Reports Q4 Net Loss of $0.01 Per Share
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
Crescita Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Crescita Therapeutics Brief: Q4 EPS Basic and Diluted Loss $0.01
Crescita Reports Q4 and Fiscal 2023 Results
Crescita Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Tranche Update on Crescita Therapeutics Inc.'s Equity Buyback Plan announced on August 29, 2023.
Crescita Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Crescita Reports Third Quarter 2023 Results
Crescita Therapeutics Obtains TSX Approval for Normal Course Issuer Bid
Crescita Therapeutics Brief: Announced Approval of Normal Course Issuer Bid
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita Therapeutics Inc. announces an Equity Buyback for 1,821,616 shares, representing 8.94% of its issued share capital.
Crescita Therapeutics Inc. authorizes a Buyback Plan.
- Crescita Therapeutics Brief: Q2 Revenue $5.162 Million; Ending cash was $10,226, down $49 for the quarter
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CTX
  4. Actualités Crescita Therapeutics Inc.
  5. Autres langues